DVAX: יתרות מזומנים למניה Dynavax Pharma

סמל ולוגו של המותג Dynavax Technologies (DVAX)

Dynavax Technologies is developing partnerships with global pharma behemoths by providing adjuvants to enhance immunity. Cash per share serves as an indicator of the issuer's financial stability, where the level of 5.50 reflects the current magnitude of liquidity. Growth is based on the success of Heplisav-B and new tests. High physician confidence confirms the status of a reliable player that has moved past the startup stage.

Dynavax Corp (DVAX): מזומנים למניה אחת מ-04.07.2022 עד 21.02.2026

פילוחים אנליטיים של חברת Dynavax Pharma (DVAX)

- מחיר ותחזית קונצנזוס למחירים:
- נתוני מזומנים ותזרימי מזומנים:
ניתוח מסכם של החברה:DVAX (Dynavax Technologies Corporation)
סחורת הדגל של Dynavax Corp

The commercialization of Heplisav-B and the development of the CpG 1018 adjuvant directly impact the cash per share of Dynavax Technologies (DVAX), reflecting its ability to fund clinical trials without external borrowing. This indicator is calculated by dividing total liquid assets by the number of shares outstanding, allowing investors to assess internal financial reserves and minimize the risks of capital drawdown.